기면증 신규 치료법 보고서(2026년)(2분기판)

The Global Narcolepsy Emerging Therapies Market is set to reach USD 37.44 million in 2035, growing at a CAGR of 10.5% from USD 15.29 million in 2026.

Narcolepsy is a chronic neurological disorder characterized by excessive daytime sleepiness, cataplexy, sleep paralysis, hypnagogic hallucinations, and fragmented nighttime sleep. Existing therapies primarily provide symptomatic relief; however, emerging treatments are increasingly designed to restore normal sleep-wake regulation by targeting orexin deficiency and other underlying neurological mechanisms. Advances in molecular neuroscience, biomarker research, and precision medicine are accelerating the development of next-generation therapies with the potential to significantly improve long-term patient outcomes.

Market Drivers

Rapid Progress in Orexin-Based Therapeutics

The discovery of orexin deficiency as the primary biological cause of Narcolepsy Type 1 has transformed therapeutic development. Multiple pharmaceutical and biotechnology companies are advancing orexin receptor agonists that aim to restore physiological wakefulness rather than simply reducing symptoms

Increasing Investment in Rare Neurological Disorders

Growing recognition of rare neurological diseases, supportive orphan drug regulations, and increased funding for neuroscience research continue to accelerate development of innovative narcolepsy therapies. These factors have strengthened global interest in first-in-class and disease-modifying treatment approaches.

Rising Demand for Improved Treatment Outcomes

Many patients continue to experience persistent excessive daytime sleepiness and cataplexy despite currently available therapies. This unmet clinical need continues to drive development of therapies capable of delivering improved efficacy, better tolerability, simplified dosing, and long-term disease management.

Expanding Precision Medicine

Advances in biomarkers, molecular diagnostics, and precision neuroscience are supporting individualized treatment strategies and improving patient selection during clinical development, increasing the likelihood of successful therapeutic outcomes.

Market Restraints

Small Patient Population

Narcolepsy remains a rare disorder, making patient recruitment for clinical trials challenging and limiting opportunities for large-scale clinical studies.

High Research and Development Costs

Developing innovative neurological therapies requires substantial investment in long-term clinical research, safety evaluation, and regulatory approval, increasing overall development costs.

Complex Regulatory Requirements

Emerging therapies must demonstrate meaningful improvements over existing symptomatic treatments while maintaining acceptable long-term safety, creating significant regulatory and clinical challenges.

Emerging Therapy and Technology Insights

The global narcolepsy emerging therapies market can be segmented by development stage, therapeutic approach, mechanism of action, route of administration, and geography.

By development stage, the market includes preclinical research, Phase I, Phase II, Phase III, and regulatory review. The pipeline is becoming increasingly mature, with several candidates progressing through mid-stage and late-stage clinical development.

By therapeutic approach, emerging treatments include orexin receptor agonists, wake-promoting agents, histamine H3 receptor antagonists/inverse agonists, monoaminergic modulators, gene-based therapies, immunomodulatory therapies, and combination therapies. Orexin receptor agonists represent the most significant area of innovation because they directly target the underlying pathophysiology of Narcolepsy Type 1 rather than providing only symptomatic relief.

By mechanism of action, investigational therapies focus on orexin signaling restoration, histamine pathway modulation, dopamine and norepinephrine regulation, neurotransmitter modulation, neuroprotective mechanisms, and precision neurological intervention. Multiple companies are pursuing differentiated mechanisms designed to improve both wakefulness and overall sleep quality.

By route of administration, therapies include oral, intranasal, injectable, and extended-release formulations, with oral therapies remaining the preferred option for long-term disease management while novel delivery systems continue to improve patient convenience.

Technological innovation continues through artificial intelligence, biomarker-guided development, precision medicine, wearable sleep monitoring technologies, and digital health platforms, supporting more efficient clinical development and personalized treatment strategies.

Emerging Therapy Trends

The narcolepsy therapeutic landscape continues evolving toward disease-modifying innovation.

Key trends include:

• Rapid expansion of orexin receptor agonist development.
• Increasing investment in first-in-class neurological therapies.
• Growing emphasis on disease-modifying treatment strategies.
• Expansion of precision medicine and biomarker research.
• Development of long-acting and convenient treatment formulations.
• Increasing collaboration between pharmaceutical companies and academic research institutions.
• Greater integration of digital technologies into clinical development and patient monitoring.

Regional Insights

North America remains the leading region for emerging narcolepsy therapies because of advanced neuroscience research, well-established sleep medicine centers, supportive orphan drug policies, and significant pharmaceutical investment. The region continues to lead innovation in orexin-targeted drug development.

Europe maintains a strong position through collaborative neurological research, expanding clinical trial activity, and favorable regulatory frameworks supporting rare disease innovation.

Asia-Pacific is expected to experience the fastest growth owing to expanding biotechnology capabilities, increasing healthcare expenditure, improved diagnosis, and rising participation in multinational clinical research programs.

Latin America and the Middle East & Africa continue strengthening research capabilities and expanding participation in international clinical studies, although commercialization remains at an earlier stage.

Competitive Landscape

The narcolepsy emerging therapies landscape includes multinational pharmaceutical companies, biotechnology firms, academic research organizations, and neuroscience-focused developers.

Leading organizations continue investing in orexin receptor agonists, histamine pathway modulators, wake-promoting agents, precision neurology, and next-generation sleep disorder therapies. Strategic collaborations, licensing agreements, mergers and acquisitions, and co-development partnerships remain central to accelerating innovation and commercialization. Key companies include Takeda Pharmaceutical Company Limited, Alkermes plc, Centessa Pharmaceuticals plc, Axsome Therapeutics Inc., and Idorsia Ltd.

Future Outlook

The future of narcolepsy treatment will be shaped by continued advances in orexin biology, precision neuroscience, personalized medicine, and disease-modifying therapeutic approaches. Orexin receptor agonists are expected to redefine future treatment by addressing the underlying biological mechanisms responsible for narcolepsy rather than simply managing symptoms.

Continued progress in clinical development, supportive regulatory pathways, and increasing investment in neuroscience research are expected to expand treatment options and improve long-term patient outcomes through 2035.

Conclusion

The Global Narcolepsy Emerging Therapies Market is positioned for strong growth through 2035, supported by rapid scientific advances, expanding clinical research, and increasing demand for innovative disease-modifying therapies. Although rare disease development presents challenges related to patient recruitment, regulatory complexity, and research costs, continued innovation in orexin-targeted therapies, precision medicine, and next-generation neurological treatments is expected to transform narcolepsy management while creating substantial opportunities for pharmaceutical companies, biotechnology firms, healthcare providers, and investors.

Key Benefits of this Report

• Comprehensive analysis of the global narcolepsy emerging therapies landscape.
• Detailed evaluation of investigational therapies, novel mechanisms of action, and clinical development progress.
• Competitive assessment of pipeline innovation, strategic collaborations, and commercialization opportunities.
• Insights into precision medicine, neuroscience innovation, and future therapeutic trends.
• Valuable resource for pharmaceutical companies, biotechnology firms, researchers, investors, consultants, and healthcare organizations.

What Businesses Use Our Reports For

Pipeline assessment, competitive intelligence, clinical development planning, licensing and partnership evaluation, commercialization strategy, investment analysis, portfolio optimization, regulatory planning, and long-term strategic decision-making.

Report Coverage

• Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global narcolepsy emerging therapies landscape by development stage, therapeutic approach, mechanism of action, route of administration, and geography
• Evaluation of investigational therapies, clinical development progress, regulatory landscape, competitive positioning, and commercialization opportunities
• Assessment of strategic collaborations, licensing activities, innovation trends, mergers and acquisitions, and future market dynamics
• Analysis of orexin receptor agonists, wake-promoting agents, histamine H3 receptor antagonists/inverse agonists, monoaminergic modulators, gene-based therapies, immunomodulatory approaches, precision medicine technologies, and emerging therapeutic opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 Key Findings
• 1.3 Treatment Landscape Highlights
• 1.4 Current Standard of Care Overview
• 1.5 Emerging Treatment Trends
• 1.6 Unmet Needs Assessment
• 1.7 Strategic Insights
• 1.8 Future Outlook

2. Disease Overview

• 2.1 Introduction to Narcolepsy
• 2.2 Disease Classification
  • 2.2.1 Narcolepsy Type 1
  • 2.2.2 Narcolepsy Type 2
  • 2.2.3 Secondary Narcolepsy
• 2.3 Disease Pathophysiology
• 2.4 Orexin/Hypocretin Deficiency Mechanism
• 2.5 Epidemiology Overview
• 2.6 Clinical Manifestations
  • 2.6.1 Excessive Daytime Sleepiness
  • 2.6.2 Cataplexy
  • 2.6.3 Sleep Paralysis
  • 2.6.4 Hypnagogic Hallucinations
  • 2.6.5 Fragmented Nighttime Sleep
• 2.7 Disease Burden Assessment
• 2.8 Unmet Medical Needs

3. Treatment Landscape Overview

• 3.1 Evolution of Narcolepsy Treatment
• 3.2 Historical Treatment Milestones
• 3.3 Current Treatment Paradigm
• 3.4 Treatment Algorithm Analysis
• 3.5 Patient Journey and Treatment Flow
• 3.6 Treatment Challenges
• 3.7 Future Treatment Direction

4. Pharmacological Treatment Landscape

• 4.1 Wake-Promoting Agents
  • 4.1.1 Treatment Overview
  • 4.1.2 Clinical Benefits
  • 4.1.3 Safety Profile
  • 4.1.4 Prescribing Trends
  • 4.1.5 Future Outlook
• 4.2 Sodium Oxybate Therapies
  • 4.2.1 Treatment Overview
  • 4.2.2 Clinical Benefits
  • 4.2.3 Safety Profile
  • 4.2.4 Prescribing Trends
  • 4.2.5 Future Outlook
• 4.3 Low-Sodium Oxybate Therapies
  • 4.3.1 Treatment Overview
  • 4.3.2 Clinical Benefits
  • 4.3.3 Safety Profile
  • 4.3.4 Prescribing Trends
  • 4.3.5 Future Outlook
• 4.4 Histamine H3 Receptor Antagonists/Inverse Agonists
  • 4.4.1 Treatment Overview
  • 4.4.2 Clinical Benefits
  • 4.4.3 Safety Profile
  • 4.4.4 Prescribing Trends
  • 4.4.5 Future Outlook
• 4.5 Central Nervous System Stimulants
  • 4.5.1 Treatment Overview
  • 4.5.2 Clinical Benefits
  • 4.5.3 Safety Profile
  • 4.5.4 Prescribing Trends
  • 4.5.5 Future Outlook
• 4.6 Antidepressants for Cataplexy Management
  • 4.6.1 Treatment Overview
  • 4.6.2 Clinical Benefits
  • 4.6.3 Safety Profile
  • 4.6.4 Prescribing Trends
  • 4.6.5 Future Outlook

5. Non-Pharmacological Treatment Landscape

• 5.1 Lifestyle Management Approaches
  • 5.1.1 Scheduled Naps
  • 5.1.2 Sleep Hygiene Interventions
  • 5.1.3 Behavioral Modifications
  • 5.1.4 Future Outlook
• 5.2 Cognitive and Behavioral Interventions
  • 5.2.1 Cognitive Behavioral Therapy
  • 5.2.2 Patient Education Programs
  • 5.2.3 Supportive Care Strategies
  • 5.2.4 Future Outlook
• 5.3 Multidisciplinary Care Models
  • 5.3.1 Sleep Specialist Management
  • 5.3.2 Neurology-Based Care
  • 5.3.3 Integrated Care Approaches
  • 5.3.4 Future Outlook

6. Treatment Landscape by Disease Type

• 6.1 Narcolepsy Type 1
  • 6.1.1 Current Treatment Practices
  • 6.1.2 Treatment Utilization Trends
  • 6.1.3 Future Outlook
• 6.2 Narcolepsy Type 2
  • 6.2.1 Current Treatment Practices
  • 6.2.2 Treatment Utilization Trends
  • 6.2.3 Future Outlook
• 6.3 Pediatric Narcolepsy
  • 6.3.1 Current Treatment Practices
  • 6.3.2 Treatment Utilization Trends
  • 6.3.3 Future Outlook
• 6.4 Adult Narcolepsy
  • 6.4.1 Current Treatment Practices
  • 6.4.2 Treatment Utilization Trends
  • 6.4.3 Future Outlook

7. Treatment Landscape by Symptom Management

• 7.1 Excessive Daytime Sleepiness
  • 7.1.1 Current Treatment Options
  • 7.1.2 Treatment Adoption Trends
  • 7.1.3 Future Outlook
• 7.2 Cataplexy
  • 7.2.1 Current Treatment Options
  • 7.2.2 Treatment Adoption Trends
  • 7.2.3 Future Outlook
• 7.3 Sleep Paralysis
  • 7.3.1 Current Treatment Options
  • 7.3.2 Treatment Adoption Trends
  • 7.3.3 Future Outlook
• 7.4 Hallucinations
  • 7.4.1 Current Treatment Options
  • 7.4.2 Treatment Adoption Trends
  • 7.4.3 Future Outlook
• 7.5 Nighttime Sleep Disturbances
  • 7.5.1 Current Treatment Options
  • 7.5.2 Treatment Adoption Trends
  • 7.5.3 Future Outlook

8. Emerging Treatment Landscape

• 8.1 Orexin Receptor Agonists
  • 8.1.1 Clinical Development Status
  • 8.1.2 Mechanism of Action
  • 8.1.3 Competitive Assessment
  • 8.1.4 Future Outlook
• 8.2 Novel Wake-Promoting Agents
  • 8.2.1 Clinical Development Status
  • 8.2.2 Mechanism of Action
  • 8.2.3 Competitive Assessment
  • 8.2.4 Future Outlook
• 8.3 Immunomodulatory Therapies
  • 8.3.1 Clinical Development Status
  • 8.3.2 Mechanism of Action
  • 8.3.3 Competitive Assessment
  • 8.3.4 Future Outlook
• 8.4 Gene and Cell-Based Therapies
  • 8.4.1 Clinical Development Status
  • 8.4.2 Mechanism of Action
  • 8.4.3 Competitive Assessment
  • 8.4.4 Future Outlook

9. Treatment Guidelines and Clinical Practice

• 9.1 International Treatment Guidelines
• 9.2 American Academy of Sleep Medicine Recommendations
• 9.3 European Treatment Recommendations
• 9.4 Japanese Treatment Recommendations
• 9.5 Treatment Sequencing Strategies
• 9.6 Physician Prescribing Patterns
• 9.7 Future Guideline Evolution

10. Geographical Analysis

• 10.1 North America
  • 10.1.1 Treatment Utilization Trends
  • 10.1.2 Standard of Care Assessment
  • 10.1.3 Access to Treatment
  • 10.1.4 Reimbursement Environment
  • 10.1.5 Key Market Drivers
  • 10.1.6 Growth Opportunities
• 10.2 Europe
  • 10.2.1 Treatment Utilization Trends
  • 10.2.2 Standard of Care Assessment
  • 10.2.3 Access to Treatment
  • 10.2.4 Reimbursement Environment
  • 10.2.5 Key Market Drivers
  • 10.2.6 Growth Opportunities
• 10.3 Asia-Pacific
  • 10.3.1 Treatment Utilization Trends
  • 10.3.2 Standard of Care Assessment
  • 10.3.3 Access to Treatment
  • 10.3.4 Reimbursement Environment
  • 10.3.5 Key Market Drivers
  • 10.3.6 Growth Opportunities
• 10.4 Latin America
  • 10.4.1 Treatment Utilization Trends
  • 10.4.2 Standard of Care Assessment
  • 10.4.3 Access to Treatment
  • 10.4.4 Reimbursement Environment
  • 10.4.5 Key Market Drivers
  • 10.4.6 Growth Opportunities
• 10.5 Middle East & Africa
  • 10.5.1 Treatment Utilization Trends
  • 10.5.2 Standard of Care Assessment
  • 10.5.3 Access to Treatment
  • 10.5.4 Reimbursement Environment
  • 10.5.5 Key Market Drivers
  • 10.5.6 Growth Opportunities

11. Key Countries Analysis

• 11.1 United States
  • 11.1.1 Treatment Utilization Trends
  • 11.1.2 Prescribing Patterns
  • 11.1.3 Access to Treatment
  • 11.1.4 Reimbursement Environment
  • 11.1.5 Key Market Drivers
  • 11.1.6 Growth Opportunities
• 11.2 Canada
  • 11.2.1 Treatment Utilization Trends
  • 11.2.2 Prescribing Patterns
  • 11.2.3 Access to Treatment
  • 11.2.4 Reimbursement Environment
  • 11.2.5 Key Market Drivers
  • 11.2.6 Growth Opportunities
• 11.3 Germany
  • 11.3.1 Treatment Utilization Trends
  • 11.3.2 Prescribing Patterns
  • 11.3.3 Access to Treatment
  • 11.3.4 Reimbursement Environment
  • 11.3.5 Key Market Drivers
  • 11.3.6 Growth Opportunities
• 11.4 United Kingdom
  • 11.4.1 Treatment Utilization Trends
  • 11.4.2 Prescribing Patterns
  • 11.4.3 Access to Treatment
  • 11.4.4 Reimbursement Environment
  • 11.4.5 Key Market Drivers
  • 11.4.6 Growth Opportunities
• 11.5 France
  • 11.5.1 Treatment Utilization Trends
  • 11.5.2 Prescribing Patterns
  • 11.5.3 Access to Treatment
  • 11.5.4 Reimbursement Environment
  • 11.5.5 Key Market Drivers
  • 11.5.6 Growth Opportunities
• 11.6 Italy
  • 11.6.1 Treatment Utilization Trends
  • 11.6.2 Prescribing Patterns
  • 11.6.3 Access to Treatment
  • 11.6.4 Reimbursement Environment
  • 11.6.5 Key Market Drivers
  • 11.6.6 Growth Opportunities
• 11.7 Spain
  • 11.7.1 Treatment Utilization Trends
  • 11.7.2 Prescribing Patterns
  • 11.7.3 Access to Treatment
  • 11.7.4 Reimbursement Environment
  • 11.7.5 Key Market Drivers
  • 11.7.6 Growth Opportunities
• 11.8 China
  • 11.8.1 Treatment Utilization Trends
  • 11.8.2 Prescribing Patterns
  • 11.8.3 Access to Treatment
  • 11.8.4 Reimbursement Environment
  • 11.8.5 Key Market Drivers
  • 11.8.6 Growth Opportunities
• 11.9 Japan
  • 11.9.1 Treatment Utilization Trends
  • 11.9.2 Prescribing Patterns
  • 11.9.3 Access to Treatment
  • 11.9.4 Reimbursement Environment
  • 11.9.5 Key Market Drivers
  • 11.9.6 Growth Opportunities
• 11.10 India
  • 11.10.1 Treatment Utilization Trends
  • 11.10.2 Prescribing Patterns
  • 11.10.3 Access to Treatment
  • 11.10.4 Reimbursement Environment
  • 11.10.5 Key Market Drivers
  • 11.10.6 Growth Opportunities
• 11.11 South Korea
  • 11.11.1 Treatment Utilization Trends
  • 11.11.2 Prescribing Patterns
  • 11.11.3 Access to Treatment
  • 11.11.4 Reimbursement Environment
  • 11.11.5 Key Market Drivers
  • 11.11.6 Growth Opportunities
• 11.12 Australia
  • 11.12.1 Treatment Utilization Trends
  • 11.12.2 Prescribing Patterns
  • 11.12.3 Access to Treatment
  • 11.12.4 Reimbursement Environment
  • 11.12.5 Key Market Drivers
  • 11.12.6 Growth Opportunities

12. Company Profiles

• 12.1 Jazz Pharmaceuticals plc
  • 12.1.1 Overview
  • 12.1.2 Financials
  • 12.1.3 Narcolepsy Treatment Portfolio
  • 12.1.4 Commercial Strategy
  • 12.1.5 Key Products
  • 12.1.6 Market Position
  • 12.1.7 Strategic Collaborations
  • 12.1.8 Recent Developments
• 12.2 Harmony Biosciences Holdings, Inc.
  • 12.2.1 Overview
  • 12.2.2 Financials
  • 12.2.3 Narcolepsy Treatment Portfolio
  • 12.2.4 Commercial Strategy
  • 12.2.5 Key Products
  • 12.2.6 Market Position
  • 12.2.7 Strategic Collaborations
  • 12.2.8 Recent Developments
• 12.3 Avadel Pharmaceuticals plc
  • 12.3.1 Overview
  • 12.3.2 Financials
  • 12.3.3 Narcolepsy Treatment Portfolio
  • 12.3.4 Commercial Strategy
  • 12.3.5 Key Products
  • 12.3.6 Market Position
  • 12.3.7 Strategic Collaborations
  • 12.3.8 Recent Developments
• 12.4 Takeda Pharmaceutical Company Limited
  • 12.4.1 Overview
  • 12.4.2 Financials
  • 12.4.3 Narcolepsy Treatment Portfolio
  • 12.4.4 Commercial Strategy
  • 12.4.5 Key Products
  • 12.4.6 Market Position
  • 12.4.7 Strategic Collaborations
  • 12.4.8 Recent Developments
• 12.5 Axsome Therapeutics, Inc.
  • 12.5.1 Overview
  • 12.5.2 Financials
  • 12.5.3 Narcolepsy Treatment Portfolio
  • 12.5.4 Commercial Strategy
  • 12.5.5 Key Products
  • 12.5.6 Market Position
  • 12.5.7 Strategic Collaborations
  • 12.5.8 Recent Developments
• 12.6 Centessa Pharmaceuticals plc
  • 12.6.1 Overview
  • 12.6.2 Financials
  • 12.6.3 Narcolepsy Treatment Portfolio
  • 12.6.4 Commercial Strategy
  • 12.6.5 Key Products
  • 12.6.6 Market Position
  • 12.6.7 Strategic Collaborations
  • 12.6.8 Recent Developments
• 12.7 Alkermes plc
  • 12.7.1 Overview
  • 12.7.2 Financials
  • 12.7.3 Narcolepsy Treatment Portfolio
  • 12.7.4 Commercial Strategy
  • 12.7.5 Key Products
  • 12.7.6 Market Position
  • 12.7.7 Strategic Collaborations
  • 12.7.8 Recent Developments
• 12.8 NLS Pharmaceutics Ltd.
  • 12.8.1 Overview
  • 12.8.2 Financials
  • 12.8.3 Narcolepsy Treatment Portfolio
  • 12.8.4 Commercial Strategy
  • 12.8.5 Key Products
  • 12.8.6 Market Position
  • 12.8.7 Strategic Collaborations
  • 12.8.8 Recent Developments
• 12.9 Aardvark Therapeutics, Inc.
  • 12.9.1 Overview
  • 12.9.2 Financials
  • 12.9.3 Narcolepsy Treatment Portfolio
  • 12.9.4 Commercial Strategy
  • 12.9.5 Key Products
  • 12.9.6 Market Position
  • 12.9.7 Strategic Collaborations
  • 12.9.8 Recent Developments
• 12.10 Zevra Therapeutics, Inc.
  • 12.10.1 Overview
  • 12.10.2 Financials
  • 12.10.3 Narcolepsy Treatment Portfolio
  • 12.10.4 Commercial Strategy
  • 12.10.5 Key Products
  • 12.10.6 Market Position
  • 12.10.7 Strategic Collaborations
  • 12.10.8 Recent Developments

13. Treatment Gap Analysis

• 13.1 Unmet Clinical Needs
• 13.2 Treatment Limitations Assessment
• 13.3 Access and Affordability Challenges
• 13.4 Innovation Opportunities
• 13.5 Future Treatment Potential

14. Future Outlook and Strategic Recommendations

• 14.1 Emerging Treatment Trends
• 14.2 Orexin-Based Therapy Market Potential
• 14.3 Innovation Roadmap
• 14.4 Strategic Opportunities for Stakeholders
• 14.5 Future Treatment Landscape Outlook

15. Research Methodology

• 15.1 Primary Research
• 15.2 Secondary Research
• 15.3 Treatment Landscape Assessment Framework
• 15.4 Data Validation and Triangulation
• 15.5 Assumptions and Limitations

16. Appendix

• 16.1 Abbreviations
• 16.2 Glossary of Terms
• 16.3 References
• 16.4 List of Tables
• 16.5 List of Figures
• 16.6 Regulatory Sources
• 16.7 Company Sources
• 16.8 Clinical Guidelines Sources
• 16.9 Scientific Literature Sources